ARPA-H Funds WFIRM-Led Program For On-Demand Bioprinted Kidneys

A major new federal investment is accelerating efforts to address the nation’s kidney donor shortage through advanced bioprinting. With support from ARPA‑H, researchers are developing implantable, vascularized kidney tissue engineered from a patient’s own cells. This work brings together cell manufacturing, custom bioinks, bioprinting platforms, and bioreactor technologies to create functional tissue capable of supporting renal function in patients with chronic kidney disease. By integrating these technologies into a unified workflow, the team aims to establish a reliable source of personalized kidney tissue that eliminates reliance on scarce donor organs.

Explore the full article to learn how this program could reshape the future of regenerative medicine and organ replacement.